ADR reporting may become a redundant, monotonous and boring activity for faithful reporters if pharmacovigilance centers do not constantly stimulate reporters’ interest. How can PV centers best achieve this?
The reporters should get feedback regarding the causality analysis and further precautions to be observed for the same offending drug. Then only, two way communication would be established. Just now, till ADR reporting becomes mandatory, some form of appreciation to the reporting consultants may be provided.
- Create a newsletter/formal professional publication in which you include the reported ADR.
- Split the national center into regional centers and delegate all the activities to the regional centers and hence you have a direct or better communication terms.
- Update your frequent reporter(s) with the ADR documented/reported globally by reliable organization.
- Educate reports on ADR terminology and other related issues.
- I’m sure it’s more difficult for public, but yet try to provide feedback on their specific disease, but it’s really difficult.